We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inari Medical (NARI) Posts Positive Results of FLASH Registry
Read MoreHide Full Article
Inari Medical, Inc. (NARI - Free Report) recently announced favorable outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (PE). The primary endpoint of the registry was successfully met by FlowTriever for the treatment of PE.
FLASH is a prospective, multicenter, single-arm registry assessing real-world patient outcomes after treatment of PE with FlowTriever.
The data was presented during a Late-Breaking Clinical Trial session at the recently-concluded Transcatheter Cardiovascular Therapeutics conference. The data was also simultaneously published in EuroIntervention (the official journal of EuroPCR) and the European Association of Percutaneous Cardiovascular Interventions.
The latest positive study outcome is a stepping stone for Inari Medical’s business across the world.
Significance of the Result
Per the Principal Investigator of the registry, the positive outcomes in a large patient population further emphasize the strong safety profile of the FlowTriever System while achieving substantial on-table clinical improvements and immediate symptom relief. This is a significant improvement over the mortality rate reported in the PERT registry. Thus, the data suggest that safe and rapid thrombus extraction with FlowTriever may meaningfully improve the natural course of the disease.
Inari Medical’s management believes that these results, along with the patients treated commercially, reinforce FlowTriever as a front-line therapy for PE. The company also remains committed to developing superior evidence that advances the treatment of PE, including the currently enrolling FLAME registry and PEERLESS randomized controlled trial (RCT).
Industry Prospects
Per a report by Precision Business Insights, the PE devices market was valued at $1.65 billion in 2021 and is anticipated to reach $2.26 billion by 2028 at a CAGR of 4.6%. Factors like the growing prevalence of cancer, long-term smoking addiction and an increase in the prevalence of PE diseases are likely to drive the market.
Given the market potential, the positive study outcome is likely to provide a significant boost to Inari Medical’s business globally.
Notable Developments
Last month, Inari Medical announced its planned enrollment for the DEFIANCE trial, a RCT comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis treated with the ClotTriever System versus anticoagulation only.
The same month, Inari Medical announced its second-quarter 2022 results, wherein it recorded a solid uptick in its revenues. It also accelerated the expansion of its U.S. commercial footprint and finished the quarter with more than 270 territories. Inari Medical also announced the FDA clearance and limited market release of two new products, one of which targets patients outside its core TAM.
Price Performance
Shares of the company have lost 11.2% in the past year compared with the industry’s 32.7% fall and the S&P 500's 11.8% decline.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Inari Medical carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , ShockWave Medical, Inc. (SWAV - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.
AMN Healthcare has lost 5% compared with the industry’s 36.9% fall in the past year.
ShockWave Medical, sporting a Zacks Rank #1 at present, has an estimated growth rate of 33.1% for 2023. SWAV’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
ShockWave Medical has gained 36.2% against the industry’s 32.7% fall over the past year.
McKesson, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.1%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.
McKesson has gained 73.5% against the industry’s 15.1% fall over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Inari Medical (NARI) Posts Positive Results of FLASH Registry
Inari Medical, Inc. (NARI - Free Report) recently announced favorable outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (PE). The primary endpoint of the registry was successfully met by FlowTriever for the treatment of PE.
FLASH is a prospective, multicenter, single-arm registry assessing real-world patient outcomes after treatment of PE with FlowTriever.
The data was presented during a Late-Breaking Clinical Trial session at the recently-concluded Transcatheter Cardiovascular Therapeutics conference. The data was also simultaneously published in EuroIntervention (the official journal of EuroPCR) and the European Association of Percutaneous Cardiovascular Interventions.
The latest positive study outcome is a stepping stone for Inari Medical’s business across the world.
Significance of the Result
Per the Principal Investigator of the registry, the positive outcomes in a large patient population further emphasize the strong safety profile of the FlowTriever System while achieving substantial on-table clinical improvements and immediate symptom relief. This is a significant improvement over the mortality rate reported in the PERT registry. Thus, the data suggest that safe and rapid thrombus extraction with FlowTriever may meaningfully improve the natural course of the disease.
Inari Medical’s management believes that these results, along with the patients treated commercially, reinforce FlowTriever as a front-line therapy for PE. The company also remains committed to developing superior evidence that advances the treatment of PE, including the currently enrolling FLAME registry and PEERLESS randomized controlled trial (RCT).
Industry Prospects
Per a report by Precision Business Insights, the PE devices market was valued at $1.65 billion in 2021 and is anticipated to reach $2.26 billion by 2028 at a CAGR of 4.6%. Factors like the growing prevalence of cancer, long-term smoking addiction and an increase in the prevalence of PE diseases are likely to drive the market.
Given the market potential, the positive study outcome is likely to provide a significant boost to Inari Medical’s business globally.
Notable Developments
Last month, Inari Medical announced its planned enrollment for the DEFIANCE trial, a RCT comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis treated with the ClotTriever System versus anticoagulation only.
The same month, Inari Medical announced its second-quarter 2022 results, wherein it recorded a solid uptick in its revenues. It also accelerated the expansion of its U.S. commercial footprint and finished the quarter with more than 270 territories. Inari Medical also announced the FDA clearance and limited market release of two new products, one of which targets patients outside its core TAM.
Price Performance
Shares of the company have lost 11.2% in the past year compared with the industry’s 32.7% fall and the S&P 500's 11.8% decline.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Inari Medical carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , ShockWave Medical, Inc. (SWAV - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has lost 5% compared with the industry’s 36.9% fall in the past year.
ShockWave Medical, sporting a Zacks Rank #1 at present, has an estimated growth rate of 33.1% for 2023. SWAV’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
ShockWave Medical has gained 36.2% against the industry’s 32.7% fall over the past year.
McKesson, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.1%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.
McKesson has gained 73.5% against the industry’s 15.1% fall over the past year.